Jun 2, 2026 03:56PM
Jun 2, 2026 02:02PM
Jun 2, 2026 11:15AM
Jun 2, 2026 10:12AM
Jun 2, 2026 07:16AM
Jun 2, 2026 07:00AM
Jun 2, 2026 07:00AM Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
May 7, 2026 07:30AM
Feb 26, 2026 07:30AM
Jan 28, 2026 07:30AM
Jan 28, 2026 07:30AM
Jan 7, 2026 07:30AM
Jan 7, 2026 07:30AM
Dec 19, 2025 05:13AM Vera Therapeutics (VERA) PT Raised to $66 at BofA Securities
Dec 19, 2025 03:47AM
Dec 2, 2025 03:50PM
Nov 28, 2025 06:35AM
Nov 10, 2025 06:48AM
Nov 7, 2025 06:27PM
Nov 6, 2025 09:51AM
Nov 6, 2025 09:51AM Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine
Nov 5, 2025 07:29AM
Oct 22, 2025 08:00AM
Oct 17, 2025 09:12AM
Oct 17, 2025 09:12AM
Aug 5, 2025 07:00AM
Jun 6, 2025 08:15AM
Jun 3, 2025 06:54AM Vera Therapeutics (VERA) PT Raised to $85 at H.C. Wainwright
Jun 2, 2025 07:09AM
Jun 2, 2025 06:31AM
Jun 2, 2025 06:30AM
May 6, 2025 08:00AM
Apr 3, 2025 08:04AM
Apr 3, 2025 08:00AM
Feb 27, 2025 07:29AM Vera Therapeutics (VERA) PT Raised to $61 at Guggenheim
Feb 26, 2025 08:25AM
Feb 26, 2025 08:25AM
Feb 18, 2025 12:19PM
Nov 18, 2024 08:00AM
Nov 11, 2024 08:00AM
Nov 7, 2024 08:00AM
Oct 26, 2024 07:30PM Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
Oct 2, 2024 06:31AM
Oct 2, 2024 06:30AM
Oct 2, 2024 06:30AM
Oct 2, 2024 06:30AM
Sep 16, 2024 08:00AM
Sep 16, 2024 08:00AM
Sep 12, 2024 08:00AM Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
Aug 8, 2024 08:00AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All